Evogene Ltd. Reports Q2 2024 Financial Results
Ticker: EVGN · Form: 6-K · Filed: Aug 22, 2024 · CIK: 1574565
Sentiment: neutral
Topics: financial-results, quarterly-report
TL;DR
Evogene dropped Q2 earnings on 8/22, check the 6-K for details.
AI Summary
Evogene Ltd. announced its financial results for the second quarter ended June 30, 2024, on August 22, 2024. The company is a foreign private issuer filing a Form 6-K report.
Why It Matters
This filing provides investors with an update on Evogene's financial performance for the second quarter of 2024, which is crucial for assessing the company's current operational health and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial results filing and does not introduce new significant risks.
Key Players & Entities
- Evogene Ltd. (company) — Registrant
- June 30, 2024 (date) — End of second quarter
- August 22, 2024 (date) — Date of announcement and filing
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to report Evogene Ltd.'s financial results for the second quarter ended June 30, 2024.
When did Evogene Ltd. announce its Q2 2024 financial results?
Evogene Ltd. announced its financial results for the second quarter ended June 30, 2024, on August 22, 2024.
What exhibit is being furnished with this Form 6-K?
Exhibit 99.1, a press release announcing the financial results, is being furnished with this Form 6-K.
Is Evogene Ltd. required to file annual reports under Form 20-F or Form 40-F?
Evogene Ltd. is required to file annual reports under Form 20-F.
What is the company's principal executive office address?
The company's principal executive office is located at 13 Gad Feinstein Street, Park Rehovot, Rehovot 7638517, Israel.
Filing Stats: 380 words · 2 min read · ~1 pages · Grade level 10.6 · Accepted 2024-08-22 07:00:28
Filing Documents
- zk2431907.htm (6-K) — 15KB
- exhibit_99-1.htm (EX-99.1) — 635KB
- exhibit_99-2.htm (EX-99.2) — 46KB
- exhibit_99-2slide1.jpg (GRAPHIC) — 192KB
- exhibit_99-2slide2.jpg (GRAPHIC) — 269KB
- exhibit_99-2slide3.jpg (GRAPHIC) — 122KB
- exhibit_99-2slide4.jpg (GRAPHIC) — 186KB
- exhibit_99-2slide5.jpg (GRAPHIC) — 156KB
- exhibit_99-2slide6.jpg (GRAPHIC) — 122KB
- exhibit_99-2slide7.jpg (GRAPHIC) — 182KB
- exhibit_99-2slide8.jpg (GRAPHIC) — 121KB
- exhibit_99-2slide9.jpg (GRAPHIC) — 149KB
- exhibit_99-2slide10.jpg (GRAPHIC) — 160KB
- exhibit_99-2slide11.jpg (GRAPHIC) — 136KB
- exhibit_99-2slide12.jpg (GRAPHIC) — 128KB
- exhibit_99-2slide13.jpg (GRAPHIC) — 122KB
- exhibit_99-2slide14.jpg (GRAPHIC) — 236KB
- exhibit_99-2slide15.jpg (GRAPHIC) — 267KB
- exhibit_99-2slide16.jpg (GRAPHIC) — 157KB
- exhibit_99-2slide17.jpg (GRAPHIC) — 123KB
- exhibit_99-2slide18.jpg (GRAPHIC) — 118KB
- exhibit_99-2slide19.jpg (GRAPHIC) — 148KB
- exhibit_99-2slide20.jpg (GRAPHIC) — 117KB
- exhibit_99-2slide21.jpg (GRAPHIC) — 148KB
- exhibit_99-2slide22.jpg (GRAPHIC) — 171KB
- exhibit_99-2slide23.jpg (GRAPHIC) — 206KB
- exhibit_99-2slide24.jpg (GRAPHIC) — 226KB
- exhibit_99-2slide25.jpg (GRAPHIC) — 166KB
- exhibit_99-2slide26.jpg (GRAPHIC) — 138KB
- exhibit_99-2slide27.jpg (GRAPHIC) — 123KB
- exhibit_99-2slide28.jpg (GRAPHIC) — 101KB
- exhibit_99-2slide29.jpg (GRAPHIC) — 123KB
- exhibit_99-2slide30.jpg (GRAPHIC) — 113KB
- exhibit_99-2slide31.jpg (GRAPHIC) — 124KB
- image0.jpg (GRAPHIC) — 295KB
- 0001178913-24-002732.txt ( ) — 7787KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission File Number: 001-36187 EVOGENE LTD. (Translation of Registrant's Name into English) 13 Gad Feinstein Street, Park Rehovot Rehovot 7638517, Israel (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F CONTENTS On August 22, 2024, Evogene Ltd. (" Evogene ") announced its financial results for the second quarter ended June 30, 2024. A Copy of the press release announcing those results is furnished as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K (this " Form 6-K ") and is incorporated herein by reference. Evogene is holding a conference call on August 22, 2024 to discuss its quarterly results for the quarter ended June 30, 2024 and, in connection with that call, will make available to its investors a slide presentation to provide additional information regarding its business and its financial results. That slide presentation is attached as Exhibit 99.2 to this Form 6-K and is incorporated herein by reference. The GAAP financial statements tables contained in the press release attached as Exhibit 99.1 to this Form 6-K are incorporated by reference in the registration statements on Form F-3 (Securities and Exchange Commission (" SEC ") File No. 333-277565 ), and Form S-8 (SEC File Nos. 333-193788 , 333-201443 , 333-203856 and 333-259215 ) of Evogene, and will be a part thereof from the date on which this Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: August 22, 2024 EVOGENE LTD. (Registrant) By: /s/ Yaron Eldad Yaron Eldad Chief Financial Officer EXHIBIT INDEX EXHIBIT NO. DESCRIPTION 99.1 Press Release: Evogene Reports Second Quarter 2024 Financial Results. 99.2 Slide presentation for conference call of Evogene held on August 22 2024 discussing Evogene's quarterly financial results for the second quarter of 2024.